Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma
17 juil. 2024 16h14 HE
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
28 juin 2024 16h04 HE
|
NurExone Biologic Inc
Prestigious Eye Institute Exploring New Indication for NurExone’s ExoPTEN
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
08 mai 2024 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) --...
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
29 avr. 2024 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
– New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron – MELBOURNE, Australia and SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX:...
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
17 avr. 2024 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing...
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
10 avr. 2024 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
26 mars 2024 10h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company...
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
20 févr. 2024 10h25 HE
|
ALTERITY THERAPEUTICS LIMITED
– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2...
Optical Imaging Market size worth $ 5.6 Billion, Globally, by 2031 at 12.82% CAGR – Report By Verified Market Research®
13 févr. 2024 10h00 HE
|
Verified Market Research
Jersey City, New Jersey, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Global Optical Imaging Market is projected to grow at a CAGR of 12.82% from 2024 to 2031, according to a new report published by...
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology
26 avr. 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, April 26, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...